Summary of NACI statement of March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)

Published: March 11, 2022

On this page

Overview

For a primary series:

  • NACI continues to preferentially recommend that a complete primary series of an mRNA COVID-19 vaccine (Pfizer-BioNTech Comirnaty or Moderna Spikevax) should be offered to individuals in the authorized age group without contraindications to the vaccine.
  • NACI recommends that a complete primary series of an authorized recombinant protein subunit COVID-19 vaccine (Novavax Nuvaxovid) or a virus-like particle COVID-19 vaccine (Medicago Covifenz) may be offered to individuals in the authorized age group without contraindications to the vaccine who are unable or unwilling to receive an mRNA vaccine.
  • NACI recommends that a complete primary series of a viral vector COVID-19 vaccine (AstraZeneca Vaxzevria, Janssen) may be offered to individuals in the authorized age group without contraindications to the vaccine only when all other authorized COVID-19 vaccines are contraindicated.

For the full statement, please see NACI Statement: Recommendations on the use of the Medicago COVID-19 vaccine (Covifenz).

For more information on NACI's recommendations on the use of COVID-19 vaccines, please refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.

What you need to know

For the full statement, please see NACI Statement: Recommendations on the use of the Medicago COVID-19 vaccine (Covifenz).

For more information on NACI's recommendations on the use of COVID-19 vaccines, please refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.

Quotes

"NACI has reviewed the available evidence on the newly authorized Medicago Covifenz COVID-19 vaccine. Clinical trials have shown that this vaccine has a good safety profile and can prevent symptomatic COVID-19 disease, which makes it another option for people who have not yet been vaccinated against COVID-19 and who are unable or unwilling to receive an mRNA vaccine. The Committee continues to preferentially recommend the use of mRNA COVID-19 vaccines for most people because of their well-known safety profiles and the large amount of evidence that shows they provide excellent protection against severe COVID-19 outcomes. As with all COVID-19 vaccines, NACI will continue to monitor the evidence on the safety and effectiveness of the Medicago Covifenz vaccine as it is rolled out in public health immunization programs. The Committee will update recommendations if needed to ensure NACI continues to provide up to date guidance for immunization program and policy planners across the country."

Dr. Robyn Harrison, NACI Vice-chair

"I am pleased to see the first COVID-19 vaccine developed by a Canadian-based company added to Canada's COVID-19 vaccine portfolio. The authorization of the Medicago Covifenz vaccine provides another COVID-19 vaccine option for adults who have not yet been immunized against COVID-19 and who are unable or unwilling to receive an mRNA COVID-19 vaccine. We know from clinical trials that the Medicago vaccine has a good safety profile and provides protection against symptomatic COVID-19 disease. As with all vaccines, PHAC, Health Canada and NACI will continue to monitor the safety and effectiveness of the Medicago vaccine as it is used more widely. I would like to thank NACI for continuing to provide expert and timely guidance on the use of COVID-19 vaccines in Canada. I encourage anyone who has not yet received a primary series of COVID-19 vaccines to get theirs now."

Dr. Theresa Tam, Chief Public Health Officer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: